AC Immune SA (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of AC Immune in a research report issued to clients and investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune's Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.60) EPS.
Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of AC Immune in a research report on Thursday, April 3rd.
Get Our Latest Analysis on AC Immune
AC Immune Stock Up 3.0 %
Shares of ACIU traded up $0.05 during mid-day trading on Wednesday, reaching $1.53. 53,965 shares of the stock traded hands, compared to its average volume of 324,430. The stock has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $2.68. The firm has a market cap of $153.13 million, a price-to-earnings ratio of -3.32 and a beta of 1.49. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.98.
Institutional Investors Weigh In On AC Immune
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quinn Opportunity Partners LLC bought a new stake in AC Immune in the fourth quarter valued at about $27,000. Two Sigma Advisers LP acquired a new stake in shares of AC Immune during the 4th quarter valued at approximately $36,000. Boothbay Fund Management LLC bought a new position in AC Immune during the fourth quarter worth $38,000. RPO LLC acquired a new position in AC Immune in the fourth quarter worth $51,000. Finally, Jane Street Group LLC bought a new stake in AC Immune during the fourth quarter valued at $66,000. Institutional investors own 51.36% of the company's stock.
AC Immune Company Profile
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Articles
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
